STOCKS TELEGRAPH

Tag: Sonoma Pharmaceuticals

  • Sonoma (SNOA) Boosts Market Presence With UK Regulatory Success

    Sonoma (SNOA) Boosts Market Presence With UK Regulatory Success

    Shares of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) experienced a sharp increase after a significant regulatory victory in the UK. SNOA stock was up 63.94% at $3.82 as of the most recent market check. Following the company’s news that its range of acne treatments based on hypochlorous acid had been successfully registered with the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA), investor confidence skyrocketed.

    Strategic Retail Launch in Europe

    In the UK, a large health and beauty store will sell the approved products—an acne toner and a balancing serum—under its own name. More than 1,200 retailers nationwide are now scheduled to carry these products. This action represents a significant turning point in Sonoma Pharmaceuticals’ larger European distribution plan and their first significant foray into the UK consumer skincare sector.

    Dermatological Care Innovation

    With its all-natural hypochlorous acid and Sonoma’s exclusive Microcyn® technology, the acne product range provides a mild yet efficient substitute for conventional treatments like benzoyl peroxide and alcohol-based formulations. The company’s dedication to using safe, non-toxic chemicals is in line with the growing demand from customers for skincare products that are safer.

    Broadening Regulatory Footprint in the UK

    This most recent milestone comes after Sonoma’s production facilities and five of its medical goods—including skin exfoliants, hydrogel for wound care, scar management products, and wound irrigation solutions—were previously registered by the MHRA. These approvals emphasize the efficacy and safety of SNOA’s formulations, supported by clinical evidence suggesting that hypochlorous acid may successfully manage small skin lesions and irritations without hurting healthy tissue.

    Positioned for European Growth

    Sonoma Pharmaceuticals is well-positioned to increase its presence in the UK and larger European markets thanks to these regulatory achievements. The company views the UK as an important market for its dermatological and wound care products. These latest registrations’ success demonstrates SNOA’s dedication to international healthcare innovation and its potential for significant regional market expansion.

  • Sonoma Pharmaceuticals (SNOA) Gains In Pre-Hour Trading

    Sonoma Pharmaceuticals (SNOA) Gains In Pre-Hour Trading

    Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares were rising 11.90% to $3.95 as of this morning’s last pre-market check. SNOA has made a number of encouraging announcements in the last week, which have led to this notable increase in stock value.

    New MHRA Registrations Signal the UK Market’s Growth

    The Medicines & Healthcare medicines Regulatory Agency (MHRA) recently granted Sonoma Pharmaceuticals permission to register its production facility and five important medicines in the UK. The recently authorized goods include a skin exfoliator, wound hydrogel, a variety of scar management solutions, and a wound irrigation solution based on hypochlorous acid.

    With this registration, Sonoma will be able to reach a wider audience and increase its market share in the UK by introducing its cutting-edge Microcyn-based products. The business was excited about the prospects for expansion this clearance offers in the dermatology and wound care industries.

    Adopting EU Medical Device Regulations with Success

    Sonoma Pharmaceuticals has accomplished a significant regulatory milestone in Europe in addition to registering in the UK. Four of the company’s products were successfully converted to conform to the Medical Device Regulation (MDR) of the European Union. These consist of Pediacyn for atopic dermatitis, Microdacyn60 Wound Care, Microdacyn60 Hydrogel, and the scar gel Epicyn.

    Strict requirements for the performance and safety of medical devices are mandated by the MDR, which took the place of the old Medical Device Directive in 2017. A noteworthy accomplishment is Sonoma’s early adherence to these new rules, which guarantees that its goods will satisfy all safety and legal criteria before the December 2028 date.

    Evidence of Regulatory Readiness and Product Safety

    Sonoma’s dedication to product safety and regulatory vigilance is demonstrated by the successful registration and classification of its products as Class IIb medical devices in Europe. The company’s solid clinical data and capacity to adjust to changing international requirements are clearly demonstrated by the shift to MDR compliance.

  • Sonoma (SNOA) Stock Rallies After Reverse-Split Trading Begins

    Sonoma (SNOA) Stock Rallies After Reverse-Split Trading Begins

    The value Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares are increasing significantly today, indicating that the market has responded favorably to the company’s switch to a reverse-split. SNOA stock surged 9.66% to $3.49 as of the most recent check.

    Specifics of the Reverse Stock Split

    Previously this week, Sonoma Pharmaceuticals announced that it will reverse its stock split one-for-20. The split was planned to take effect on August 29, 2024, at 5:00 PM EDT. The company’s shareholders approved the reverse split during the annual meetings on August 14–23, 2024, which led to this decision.

    The Board of Directors authorized the split and set the ratio on August 23, 2024. In order to preserve Sonoma’s listing status on the Nasdaq Capital Market, a calculated strategic maneuver was made with the reverse stock split. Sonoma hopes to increase investor interest, boost stakeholder confidence, and open up new business growth options by keeping its Nasdaq listing.

    Every twenty shares of Sonoma’s common stock will convert into one new share, without altering the par value per share. Consequently, the total number of shares will reduce from approximately 20 million to around one million.

    Operational Developments

    Operationally, Sonoma Pharmaceuticals has expanded the claims for its Nanocyn Disinfectant and Sanitizer after the Australian Therapeutic Goods Administration (TGA) granted an extension. Utilizing Sonoma’s proprietary Microcyn technology, Nanocyn is manufactured for MicroSafe and has received additional approvals for its ability to effectively combat Clostridium difficile (C. diff.) and Candida auris (C. auris) in less than ten minutes.

    Nanocyn has previously been approved by the Australian Register of Therapeutic Goods for use against a variety of germs, viruses, influenza A, and SARS-CoV-2. Nanocyn is already recognized by the Environmental Protection Agency (EPA) of the United States as a disinfectant that effectively fights diseases such as MRSA, Salmonella, mpox, SARS-CoV-2, and others.

    Strategic Impact

    By tackling a variety of dangerous pathogens, these additional TGA approvals strengthen Sonoma Pharmaceuticals’ leadership in broad-use disinfection technology and reaffirm its dedication to strict safety regulations.

  • Sonoma Pharmaceuticals, Inc. (SNOA) Stock Drops Significantly Despite Promising Financial Reports for Fiscal Q4 2021

    Sonoma Pharmaceuticals, Inc. (SNOA) stock prices were down 18.88% some time after market trading commenced on July 15th, 2021, bringing the price per share down to USD$6.23 early on in the trading day.

    Partnership with EMC Pharma

    March 26th, 2021 saw the company report having entered into a new partnership with EMC Pharma in light of it having gained exclusive rights for the U.S commercialization of prescription dermatology and prescription eye care products. The pharmaceutical company was also granted non-exclusive rights to sell their wound care products into government channels. The initial term of the agreement is subject to minimum purchases and is set for five years, with the option to renew.

    Network of Partnerships

    September 2020 saw the company launch two new products, Nasocyn Nasal Care and Oracyn Oral Care in collaboration with its partner, Te Arai Biofarma Ltd. December 2020 saw the company partner up with Gabriel Science, LLC in order to penetrate the dental markets in the U.S with their HOCI product. January 2021 saw the company receive clearances in Thailand, after which the sales of Dermodacyn disinfectant commenced in Hong Kong and Thailand, through its partner, VetSynova Co. Ltd.

    Total Revenues

    Total Revenues for the quarter ended March 31st, 2021 came in at USD$2.2 million, down by USD$2.1 million as compared to the same time period of the prior year. The 50% reduction was largely driven by the USD$1.6 million decline in the U.S, which, in turn, was motivated by the decline of the company’s dermatology business. The dermatology business has since been partnered with EMC Pharma, LLC. Further compounding the year-over-year difference was USD$800,000 in revenue adjustments in relation to the overestimation of revenue in the prior-year quarter, having been determined using a look-back analysis.

    Invekra Contract

    As a result of the Invekra contract having concluded in October of 2020 resulted in a USD$0.7 million reduction in revenues generated from Latin America sales, further contributing to the yearly difference in total revenue. As per the contract, SNOA the company manufactured at low margins for Invekra. Since the conclusion of the contract, manufacturing has continued at reduced quantities but higher margins.

    Future Outlook for SNOA

    Armed with a network of partnerships secured over the past few quarters, SNOA is poised to capitalize on the chances afforded to it. The company is keen to continue its trajectory of success as it pushes for the consolidation and expansion of its market footprint around the globe. Current and potential investors are hopeful that management will be able to usher in sustained and significant increases in shareholder value.

  • Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) shares taking aerial root after this announcement

    Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) shares taking aerial root after this announcement

    Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) shares hiked 32.30%  to reach $8.11 in the pre-market session after the announcement that they have reached a license and supply agreement for exclusive rights to market and sell products in the United States for over-the-counter (OTC) dermatological products.

    Crown plans to sell Sonoma’s Microcyn technology dermal sprays and gels targeting itch and pain under Sarna, the #1 Dermatologist Recommended Anti-Itch Brand, with a unique variety of formulations to quickly relieve itch and skin irritations.

    The HOCl line of products from Sonoma is clinically proven to reduce burning, itching, and pain in patients suffering from different kinds of dermatoses, including radiation dermatitis and atopic dermatitis. Sonoma will continue to sell prescription drugs, while Crown will offer over-the-counter products.

  • Sonoma Pharmaceuticals (SNOA) announced its financial results for the 2nd quarter and 6 months

    Sonoma Pharmaceuticals (SNOA) announced its financial results for the 2nd quarter and 6 months

    Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a multinational healthcare giant, has released financial results for its second fiscal quarter and six months ended September 30, 2020, manufacturing and supplying stabilized hypochlorous acid (HOCl) drugs for a wide variety of uses, including wound treatment, eye care, nasal care, oral care, and dermatological disorders. It also announced that, because of factual irregularities, it had to restate its first-quarter financial statements for the quarter ended June 30, 2020. The key highlights for the 6 months, ended September 30, 2020

    Sonoma recently completed the transition from Petaluma, CA to Woodstock, GA during the second fiscal year All manufacturing is now achieved at the state-of-the-art Sonoma plant in Zapopan, Mexico. As a result of this reorganization, Sonoma plans to see a continuous decrease in both overhead and the cost of products sold.

    Joint research was conducted in the Journal of Hospital Infection by the University of Hong Kong and Queen Mary Hospital using Dermodacyn Disinfecting solution, a medical-grade solution manufactured by Sonoma and marketed in Hong Kong by Sonoma partner Microderm Technologies Limited.   The study found that Dermodacyn Disinfecting solution significantly decreased the viability of SARS-CoV-2 against other laboratory and domestic disinfectants that are widely used.

    As the company works with its multinational network of retail partners to increase the number of goods and markets where such products are sold, Sonoma’s international market has continued to demonstrate strength. Sonoma, for instance, partnered with its affiliate Te Arai BioFarma to launch two new nasal and oral care brands in Australia and New Zealand, as previously announced on September 9, 2020.

    With an average rise in sales and a decline in operational expenses, Sonoma’s operating efficiency tends to grow quarter after quarter. Although the COVID-19 pandemic has created a daunting global climate, the versatility of Sonoma’s product lines and global markets served has not only proved to separate Sonoma from geographical downturns, but in some countries, the company’s anti-viral and anti-bacterial drugs have seen elevated demand.

  • Top Stocks As Federal Reserve Restores Market Confidence

    Top Stocks As Federal Reserve Restores Market Confidence

    The equity markets have regained upside momentum this afternoon. This follows the Fed’s decision to keep supporting the markets.  A statement from the FOMC said that the direction the economy takes will depend heavily on the coronavirus and that the virus will significantly affect employment numbers and inflation. The Fed then added that it was ready to use a wide array of tools to support the economy.

    The Federal Reserve further stated that it would increase its levels of treasury securities, and both commercial and residential mortgage-backed securities at current prices.  The news has seen the major stock indices rally with the NASDAQ now up by 1.50%. Individual stocks are also on the rise. The most visible stock gainer today is Kodak, which is up by 500%, dwarfing the stellar day that it had in yesterday’s trading session. Besides Kodak, other stocks that have recorded significant gains this afternoon are as below:

    Tupperware Brands Corporation [NYSE:TUP]

    This is one of the biggest gainers in the day and is up by 62% this afternoon.  The rally follows the company’s strong Q2 results that have beat analyst expectations. The company announced that its diluted EPS was 60% higher than the amount that it reported in 2019.

    The company also announced that in the quarter, its cash flow from its operations was higher by $71 million compared to Q2 of 2019. Nonetheless, the company reported that due to the COVID-19 pandemic, sales declined by 16% compared to the previous quarter.  CEO Sandra Harris noted that the increase in profitability was due to the company’s commitment to improve its profit margins and strengthen the balance sheet.

    Sonoma Pharmaceuticals Inc [NASDAQ:SNOA]

    Sonoma Pharmaceuticals Inc is another top performer this afternoon and is up by 52%. These gains come just a day after the company announced that Microsafe® disinfectant had passed the compatibility test for Boeing and Airbus commercial planes. The company’s CEO Amy Trombly stated that they were happy with the tests and that they expanded the company’s potential sales in the airline market, due to the COVID-19 pandemic. She added that the company was continually looking to grow its market reach across the globe.

    Big 5 Sporting Goods Corporation [NASDAQ:BGFV]

    This is another top gainer this afternoon and is up by 49%.  Its gains come after it reported impressive Q2 results. The company announced that its net income for Q2 stood at $11.1 million and that it was reinstating dividends. It further announced that store sales shot up by 31% and that it now had a cash position of around $38 million.